PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Filgotinib - Inflammatory bowel disease

PAD Profile : Filgotinib - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, UC, high cost immunomodulator, Sequential use of biologic medicines , JAK inhibitor, Janus Kinase, Jakinib
Brand Names Include :
Jyseleca
Important Information :
Ulcerative colitis - adults only

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

03 August 2022
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of filgotinib for treating moderately to severely active ulcerative colitis in line with NICE TA792.

Filgotinib will be given a RED traffic light status. Prescribing will be by hospital specialists only using Blueteq forms for initiation & continuation

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More